Significant Ownership of Roivant Sciences Ltd.
- Large-stake filing summary
-
- Recent SEC Schedule 13D/G filings for Roivant Sciences Ltd. focus on large-stake beneficial ownership disclosures and amendments.
- Use this view to spot new large holders, amended positions, and activist-style ownership evidence.
- Manager signature
- /s/ Keyur Parekh - Keyur Parekh, Authorized Signatory
- Manager location
- London
Large-stake snapshot
1 signal
Manager
Names, identifiers, and filing context for this profile.
2 identity fields
Follow Filing Activity
Follow Roivant Sciences Ltd. with Pro and return when a new Schedule 13D/G filing changes the record on this page.
Pro alert delivery is coming soon and remains tied to source-backed filing changes rather than inferred market advice.
CIK context first
Continue from Roivant Sciences Ltd.
Significant Ownership of Roivant Sciences Ltd.
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| IMVT | Immunovant, Inc. | Common Stock, par value $0.0001 per share | 56% | $2,812,776,314 | +$413,666,650 | 113,327,007 | +17% | Roivant Sciences Ltd. | 12 Dec 2025 |
| ABUS | Arbutus Biopharma Corp | Common Shares, without par value | 20% | $127,808,150 | 38,847,462 | 0% | Roivant Sciences Ltd. | 21 Feb 2025 |
Schedules 13D/G Reported by Roivant Sciences Ltd.:
| Sym | Target | Class | Ownership | Change | Current shares | Change | Value | Reporting name | Form | Report period | Filing date |
|---|
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.